메뉴 건너뛰기




Volumn 126, Issue 6, 2015, Pages 739-745

Long-term follow-up of MCL patients treated with single-agent ibrutinib: Updated safety and efficacy results

(24)  Wang, Michael L a   Blum, Kristie A b   Martin, Peter c   Goy, Andre d   Auer, Rebecca e   Kahl, Brad S f   Jurczak, Wojciech g   Advani, Ranjana H h   Romaguera, Jorge E a   Williams, Michael E i   Barrientos, Jacqueline C j   Chmielowska, Ewa k   Radford, John l   Stilgenbauer, Stephan m   Dreyling, Martin n   Jedrzejczak, Wieslaw Wiktor o   Johnson, Peter p   Spurgeon, Stephen E q   Zhang, Liang a   Baher, Linda r   more..


Author keywords

[No Author keywords available]

Indexed keywords

IBRUTINIB; AGAMMAGLOBULINAEMIA TYROSINE KINASE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

EID: 84938752545     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-03-635326     Document Type: Article
Times cited : (354)

References (14)
  • 2
    • 84871906234 scopus 로고    scopus 로고
    • Non-Hodgkin lymphoma: The clinician's perspective - A view from the receiving end
    • Connors JM. Non-Hodgkin lymphoma: the clinician's perspective - a view from the receiving end. Mod Pathol. 2013;26(Suppl 1):S111-S118.
    • (2013) Mod Pathol , vol.26 , pp. S111-S118
    • Connors, J.M.1
  • 4
    • 84910099125 scopus 로고    scopus 로고
    • How to manage mantle cell lymphoma
    • Dreyling M, Ferrero S, Hermine O. How to manage mantle cell lymphoma. Leukemia. 2014;28(11):2117-2130.
    • (2014) Leukemia , vol.28 , Issue.11 , pp. 2117-2130
    • Dreyling, M.1    Ferrero, S.2    Hermine, O.3
  • 5
    • 84857748460 scopus 로고    scopus 로고
    • Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: An analysis from the NCCN NHL Database
    • LaCasce AS, Vandergrift JL, Rodriguez MA, et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood. 2012;119(9):2093-2099.
    • (2012) Blood , vol.119 , Issue.9 , pp. 2093-2099
    • LaCasce, A.S.1    Vandergrift, J.L.2    Rodriguez, M.A.3
  • 6
    • 0035660786 scopus 로고    scopus 로고
    • Role of Bruton's tyrosine kinase in B cell development
    • Maas A, Hendriks RW. Role of Bruton's tyrosine kinase in B cell development. Dev Immunol. 2001;8(3-4):171-181.
    • (2001) Dev Immunol , vol.8 , Issue.3-4 , pp. 171-181
    • Maas, A.1    Hendriks, R.W.2
  • 7
    • 84940031583 scopus 로고    scopus 로고
    • Pharmacyclics and Jansenn Biotech, Inc. Available at Accessed January 7, 2014
    • IMBRUVICA. (ibrutinib) prescribing information. Pharmacyclics and Jansenn Biotech, Inc. 2014. Available at http://www.imbruvica.com/docs/librariesprovider3/default-document-library/prescribing-information.pdf?sfvrsn=4. Accessed January 7, 2014.
    • (2014) (Ibrutinib) Prescribing Information
  • 8
    • 84881225049 scopus 로고    scopus 로고
    • Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
    • Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507-516.
    • (2013) N Engl J Med , vol.369 , Issue.6 , pp. 507-516
    • Wang, M.L.1    Rule, S.2    Martin, P.3
  • 10
    • 4944233187 scopus 로고    scopus 로고
    • Tumour lysis syndrome: New therapeutic strategies and classification
    • Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127(1):3-11.
    • (2004) Br J Haematol , vol.127 , Issue.1 , pp. 3-11
    • Cairo, M.S.1    Bishop, M.2
  • 11
    • 33750625445 scopus 로고    scopus 로고
    • Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
    • Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24(30):4867-4874.
    • (2006) J Clin Oncol , vol.24 , Issue.30 , pp. 4867-4874
    • Fisher, R.I.1    Bernstein, S.H.2    Kahl, B.S.3
  • 12
    • 84889099537 scopus 로고    scopus 로고
    • Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: Phase II MCL-001 (EMERGE) study
    • Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31(29):3688-3695.
    • (2013) J Clin Oncol , vol.31 , Issue.29 , pp. 3688-3695
    • Goy, A.1    Sinha, R.2    Williams, M.E.3
  • 13
    • 84904252369 scopus 로고    scopus 로고
    • Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia
    • Byrd JC, Brown JR, O'Brien S, et al RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213-223.
    • (2014) N Engl J Med , vol.371 , Issue.3 , pp. 213-223
    • Byrd, J.C.1    Brown, J.R.2    O'Brien, S.3
  • 14
    • 0036299645 scopus 로고    scopus 로고
    • Is there an increased rate of additional malignancies in patients with mantle cell lymphoma?
    • Barista I, Cabanillas F, Romaguera JE, et al. Is there an increased rate of additional malignancies in patients with mantle cell lymphoma? Ann Oncol. 2002;13(2):318-322.
    • (2002) Ann Oncol , vol.13 , Issue.2 , pp. 318-322
    • Barista, I.1    Cabanillas, F.2    Romaguera, J.E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.